Myqorzo (aficamten) / Cytokinetics, Bayer, Sanofi - LARVOL DELTA

Contractile effects of Aficamten in the human atrium. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Moreover, aficamten diminished FOC that had been elevated by a calcium sensitizer (EMD57033), a serine/threonine phosphatase inhibitor (100 µM cantharidin), 100 µM dibutyryl-cAMP, a membrane permeant 3´,5´-cyclic adenosine monophosphate (cAMP) derivative, or Bay K 8644, an activator of L-type calcium ion channels, in HAP. We conclude that aficamten diminished basal and elevated FOC in HAP, probably via reducing the calcium sensitivity of the human atrial myofilaments."

Journal • Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Heart Failure • Hypertrophic Cardiomyopathy

Benefit of aficamten in non-obstructive hypertrophic cardiomyopathy. (PubMed, Nat Rev Cardiol) - No abstract available

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Effect of cardiac myosin inhibitors on cardiac structure and myocardial fibrosis in obstructive hypertrophic cardiomyopathy: a meta-analysis of cardiac magnetic resonance outcomes. (PubMed, Clin Radiol) - "CMIs have shown efficacy in improving cardiac structure in oHCM. However, the impact on myocardial fibrosis remains unclear."

Journal • Retrospective data • Cardiomyopathy • Cardiovascular • Fibrosis • Hypertrophic Cardiomyopathy • Immunology • Obstructive Hypertrophic Cardiomyopathy

Left Ventricular Systolic Dysfunction in Long-Term Aficamten Therapy for Obstructive HCM: A FOREST-HCM Analysis (AHA 2026) - "Abstract is embargoed at this time."

Obstructive Hypertrophic Cardiomyopathy

Efficacy And Safety Of Invasive And Pharmacologic Therapies For Obstructive Hypertrophic Cardiomyopathy: A Systematic Review And Network Meta-analysis Of 8,742 Patients (HFSA 2026) - "Seven randomized controlled trials and 12 observational studies (8,742 adults with oHCM) were included, evaluating mavacamten, aficamten, septal myectomy (SM), alcohol septal ablation (ASA), metoprolol, medical therapy, and placebo. Randomized evidence supports CMIs as the most consistent pharmacologic option for short-term LVOT gradient reduction and symptom improvement in oHCM. Septal reduction therapies provided the greatest relief of provoked obstruction and showed favorable longer-term outcome signals versus medical therapy in observational analyses, although survival inferences remain limited by confounding."

Retrospective data • Review • Acute Kidney Injury • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy • Renal Disease

Association Of Aficamten Treatment With Right Ventricular Function And Pulmonary Coupling In Obstructive Hypertrophic Cardiomyopathy: Results From The SEQUOIA-HCM Trial (HFSA 2026) - P3 | "In patients with oHCM, aficamten was associated with a mild reduction in RVFWLS that remained within the normal range, alongside a significant reduction in RVSP, leading to preserved RV-PA coupling. Changes in RV strain were not associated with other clinical measures and provide reassurance regarding RV performance with aficamten treatment."

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Advancements in treatment for oHCM and clinical practice experiences with aficamten - Key takeaways and discussion (ESC 2026) - "Sponsored by Cytokinetics"

Clinical • Cardiovascular • Obstructive Hypertrophic Cardiomyopathy

Clinical experience with aficamten from the US (ESC 2026) - "Sponsored by Cytokinetics"

Clinical • Cardiovascular • Obstructive Hypertrophic Cardiomyopathy

Practical experience and considerations with aficamten in Europe (ESC 2026) - "Sponsored by Cytokinetics"

Cardiovascular • Obstructive Hypertrophic Cardiomyopathy

The evolving landscape of oHCM and aficamten in the clinical setting (ESC 2026) - "Sponsored by Cytokinetics"

Clinical • Cardiovascular • Obstructive Hypertrophic Cardiomyopathy

Advancements in treatment for oHCM and clinical practice experiences with aficamten (ESC 2026) - "Sponsored by Cytokinetics Enhance the understanding of key clinical data and real-world experience with aficamten in obstructive hypertrophic cardiomyopathy and discuss practical approaches for implementation in routine care, drawing on insights from Germany and the United States."

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Aficamten vs. Metoprolol Monotherapy in Obstructive Hypertrophic Cardiomyopathy According to Pre-Trial Treatment in MAPLE-HCM (ESC 2026) - No abstract available

Late-breaking abstract • Monotherapy • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Effect of aficamten on cardiac structure and function in patients with symptomatic nonobstructive hypertrophic cardiomyopathy - Results from the ACACIA-HCM trial (ESC 2026) - No abstract available

Clinical • Late-breaking abstract • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

ACACIA-HCM: Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy (ESC 2026) - No abstract available

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Fast forwarding care: managing obstructive hypertrophic cardiomyopathy in clinical practice with aficamten (ESC 2026) - "Sponsored by Cytokinetics"

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Fast forwarding care: managing obstructive hypertrophic cardiomyopathy in clinical practice with aficamten (ESC 2026) - "Sponsored by Cytokinetics To apply guideline-based management principles for obstructive hypertrophic cardiomyopathy in clinical practice; To identify factors guiding treatment initiation and escalation; To select appropriate therapies based on patient profiles and clinical scenarios; To implement practical approaches to initiation, monitoring, and optimisation of treatment; and To integrate case-based insights to individualise patient management."

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Fast forwarding care: managing obstructive hypertrophic cardiomyopathy in clinical practice with aficamten (ESC 2026) - "Sponsored by Cytokinetics"

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Fast forwarding care: managing obstructive hypertrophic cardiomyopathy in clinical practice with aficamten (ESC 2026) - "Sponsored by Cytokinetics To apply guideline-based management principles for obstructive hypertrophic cardiomyopathy in clinical practice; To identify factors guiding treatment initiation and escalation; To select appropriate therapies based on patient profiles and clinical scenarios; To implement practical approaches to initiation, monitoring, and optimisation of treatment; and To integrate case-based insights to individualise patient management."

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Fast forwarding care: managing obstructive hypertrophic cardiomyopathy in clinical practice with aficamten (ESC 2026) - "Sponsored by Cytokinetics"

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Fast forwarding care: managing obstructive hypertrophic cardiomyopathy in clinical practice with aficamten (ESC 2026) - "Sponsored by Cytokinetics To apply guideline-based management principles for obstructive hypertrophic cardiomyopathy in clinical practice; To identify factors guiding treatment initiation and escalation; To select appropriate therapies based on patient profiles and clinical scenarios; To implement practical approaches to initiation, monitoring, and optimisation of treatment; and To integrate case-based insights to individualise patient management."

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Fast forwarding care: managing obstructive hypertrophic cardiomyopathy in clinical practice with aficamten (ESC 2026) - "Sponsored by Cytokinetics"

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Fast forwarding care: managing obstructive hypertrophic cardiomyopathy in clinical practice with aficamten (ESC 2026) - "Sponsored by Cytokinetics To apply guideline-based management principles for obstructive hypertrophic cardiomyopathy in clinical practice; To identify factors guiding treatment initiation and escalation; To select appropriate therapies based on patient profiles and clinical scenarios; To implement practical approaches to initiation, monitoring, and optimisation of treatment; and To integrate case-based insights to individualise patient management."

Clinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Comparative efficacy and safety of invasive and pharmacologic therapies in obstructive hypertrophic cardiomyopathy: a network meta-analysis (ESC 2026) - " A PRISMA-NMA systematic review identified 7 randomized controlled trials and 12 comparative observational studies (n=8,742) evaluating mavacamten, aficamten, septal myectomy (SM), alcohol septal ablation (ASA), and conventional medical therapy. CMIs provide the most reliable short-term pharmacologic relief of obstruction with meaningful symptomatic and functional gains in randomized evidence. Septal reduction therapies remain the most potent strategies for eliminating provoked gradients and may offer durable outcome benefits in selected patients. Evidence-type–specific rankings highlight the complementary—not competing—roles of pharmacologic and invasive approaches and inform individualized treatment sequencing in oHCM."

Retrospective data • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. (PubMed, N Engl J Med) - P3 | "Among patients with symptomatic nonobstructive HCM, treatment with aficamten resulted in a significantly greater change in exercise capacity and patient-reported health status than placebo at 36 weeks. (Funded by Cytokinetics; ACACIA-HCM ClinicalTrials.gov number, NCT06081894.)."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From MAPLE-HCM. (PubMed, JACC Heart Fail) - P3 | "Aficamten was superior to metoprolol regardless of BB use at screening or prior SOC medications. This supports the primary study results and suggests no confounding by BB resistance. Consequently, aficamten can be considered an early treatment option independent of prior SOC history. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM [MAPLE-HCM; NCT05767346)."

Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy